← Back to Analyst Consensus 
GANX Buy
Gain Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 18, 2026 (22 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 31, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 11, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jul 1, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 30, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Dec 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Oct 15, 2025 | BTIG | reiterate | Buy → Buy | $9 | 52% |
| Oct 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Oct 7, 2025 | Maxim Group | maintain | Buy → Buy | $7 | 42% |
| Sep 8, 2025 | BTIG | reiterate | Buy → Buy | $9 | 52% |
| Aug 13, 2025 | Roth Capital | maintain | Buy → Buy | $6 | 53% |
| Jul 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| May 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 28, 2025 | Chardan Capital | maintain | Buy → Buy | $6 | 47% |
| Mar 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 7, 2025 | Scotiabank | initiate | — → Sector Outperform | $12 | 55% |
| Dec 24, 2024 | Roth MKM | maintain | Buy → Buy | $7 | 52% |
| Dec 5, 2024 | Roth MKM | initiate | — → Buy | $7 | 52% |
| Nov 25, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Oct 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Oct 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Sep 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Aug 9, 2024 | Chardan Capital | maintain | Buy → Buy | $6 | 47% |
| Jul 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jul 2, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| May 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| May 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| May 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Apr 25, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Apr 23, 2024 | Oppenheimer | maintain | Outperform → Outperform | $9 | 52% |
| Apr 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Mar 27, 2024 | Chardan Capital | reiterate | Buy → Buy | $6 | 47% |
| Dec 4, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| Sep 18, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Sep 12, 2023 | Maxim Group | initiate | — → Buy | $10 | 42% |
| Aug 31, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 14, 2023 | Chardan Capital | reiterate | Buy → Buy | $6 | 47% |
| Aug 14, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Jun 12, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $10 | 52% |
| May 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| May 15, 2023 | Chardan Capital | maintain | Buy → Buy | $6 | 47% |
| May 1, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $10 | 44% |
| Mar 27, 2023 | Chardan Capital | maintain | — → Buy | $5.75 | 47% |
| Dec 9, 2022 | Chardan Capital | initiate | — → Buy | $4 | 47% |
| Nov 25, 2022 | Oppenheimer | maintain | — → Outperform | $10 | 52% |
| Nov 14, 2022 | HC Wainwright & Co. | maintain | — → Buy | $10 | 44% |
| Nov 14, 2022 | BTIG | maintain | — → Buy | $10 | 52% |
| Aug 19, 2022 | B. Riley Securities | downgrade | Buy → Neutral | $5 | 54% |
| Mar 29, 2022 | B. Riley Securities | maintain | — → Buy | $16 | 54% |
| Mar 29, 2022 | HC Wainwright & Co. | initiate | — → Buy | $12 | 44% |
Price Target Trend
Mar 26, 2026 Oct 27, 2026
EPS Estimates
+1q —
0y —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days